incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-11. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
During the 1990s, Brazil saw a surge of critical and commercial success with films such as O Quatrilho (Fábio Barreto, 1995), O Que É Isso, Companheiro? (Bruno Barreto, 1997) and Central do Brasil (Walter Salles, 1998), all of which were nominated for the Academy Award for Best Foreign Language Film, the latter receiving a Best Actress nomination for Fernanda Montenegro. The 2002 crime film City of God, directed by Fernando Meirelles, was critically acclaimed, scoring 90% on Rotten Tomatoes, being placed in Roger Ebert's Best Films of the Decade list and receiving four Academy Award nominations in 2004, including Best Director. Notable film festivals in Brazil include the São Paulo and Rio de Janeiro International Film Festivals and the Gramado Festival. The film I'm Still Here, directed by Walter Salles, was nominated for Best Actress (Torres) and Best Picture at the 97th Academy Awards, and won Best International Feature Film, becoming the first-ever Brazilian produced film to win an Academy Award. The film The Secret Agent had its world premiere at the main competition of the 2025 Cannes Film Festival on 18 May 2025, where it won the Best Actor prize for Wagner Moura, the Best Director prize for Mendonça and the FIPRESCI Prize. It received further widespread critical acclaim.
Prader–Willi syndrome, with an incidence between 1 in 12,000 and 1 in 15,000 live births, is characterized by hyperphagia and food preoccupations which leads to rapid weight gain in those affected. Bardet–Biedl syndrome MOMO syndrome Leptin receptor mutations Congenital leptin deficiency Melanocortin receptor mutations In children with early-onset severe obesity (defined by an onset before ten years of age and body mass index over three standard deviations above normal), 7% harbor a single locus mutation. One study found that 80% of the offspring of two obese parents were obese, in contrast to less than 10% of the offspring of two parents who were of normal weight. The percentage of obesity that can be attributed to genetics varies from 6% to 85% depending on the population examined.
== Research == Ben-Tal's research is in computational structural biology, with an emphasis on developing computational methods to study protein structure, function, motion, and evolution. His laboratory investigates molecular systems for which computational approaches can provide information that is difficult to obtain experimentally. His research has included computational studies of membrane proteins and transporters, including the human copper transporter 1, the ATP7B copper-transporting ATPase, and sodium/proton exchangers. His group has also developed methods for predicting the structures and motions of membrane proteins and has applied computational approaches to questions in protein evolution and drug discovery.
=== Peptide based hydrogels === Peptide based hydrogels possess exceptional biocompatibility and biodegradability qualities, giving rise to their wide use of applications, particularly in biomedicine; as such, their physical properties can be fine-tuned in order to maximise their use. Methods to do this are: modulation of the amino acid sequence, pH, chirality, and increasing the number of aromatic residues. The order of amino acids within the sequence is crucial for gelation, as has been shown many times. In one example, a short peptide sequence Fmoc-Phe-Gly readily formed a hydrogel, whereas Fmoc-Gly-Phe failed to do so as a result of the two adjacent aromatic moieties being moved, hindering the aromatic interactions. Altering the pH can also have similar effects, an example involved the use of the naphthalene (Nap) modified dipeptides Nap-Gly-Ala, and Nap- Ala-Gly, where a drop in pH induced gelation of the former, but led to crystallisation of the latter. A controlled pH decrease method using glucono-δ-lactone (GdL), where the GdL is hydrolysed to gluconic acid in water is a recent strategy that has been developed as a way to form homogeneous and reproducible hydrogels. The hydrolysis is slow, which allows for a uniform pH change, and thus resulting in reproducible homogenous gels. In addition to this, the desired pH can be achieved by altering the amount of GdL added. The use of GdL has been used various times for the hydrogelation of Fmoc and Nap-dipeptides.
Sources: en.wikipedia.org
=== Dissolved gases === Oxygen dissolved in water can lead to unwanted oxidation of silicon wafers and other materials while gases like carbon dioxide lead to unwanted acidification of water and must be removed. Gases can be removed through various methods including thermal or pressure degassing, membrane degassers or chemical degassing.
=== Box office === Dredd earned $27.6 million from markets outside of North America and $13.4 million from North America, for a total of $41 million. In the UK, Dredd grossed £1.05 million ($1.7 million) from 415 cinemas during its opening weekend. This made it the weekend's number-one film, the first film restricted to audiences over 18 years of age to do so since Saw 3D in 2010. In its second weekend, the film placed number five, earning £769,381. Dredd was primarily shown in 3D in the UK, and 2D screenings were notoriously limited as the distributor denied cinemas' requests for 2D prints; the decision was considered to have limited the film's audience where 2D was their preferred format. Dredd earned a total of $6.9 million in the UK. In North America, pre-release tracking estimated that the film would gross between $8 and $10 million during its opening weekend based on its adult rating and the poor reputation of the 1995 adaptation. The film earned $2.2 million on its opening day and finished the weekend in sixth place, grossing $6.3 million from 2,506 cinemas—an average of $2,514 per cinema. The largest demographic of the opening weekend audience was over the age of 25 (69%) and male (75%). The film's North American run ended on 1 November 2012, after 42 days. Outside of the UK and North America, Dredd had its most successful total gross takings in China ($4.5 million), Russia ($4 million), and Australia ($2 million). Urban criticised the film's marketing campaign, saying that the film had "zero audience awareness. Nobody knew the movie was being released.
== External links == The Macromolecular Structure Database (MSD) at the European Bioinformatics Institute (EBI) – Serves a list of the Probable Quaternary Structure (PQS) for every protein in the Protein Data Bank (PDB). PQS server – PQS has not been updated since August 2009 PISA – The Protein Interfaces, Surfaces and Assemblies server at the MSD. EPPIC – Evolutionary Protein–Protein Interface Classification: evolutionary assessment of interfaces in crystal structures 3D complex[link removed] – Structural classification of protein complexes Proteopedia – Proteopedia Home Page The collaborative, 3D encyclopedia of proteins and other molecules. PDBWiki – PDBWiki Home Page – a website for community annotation of PDB structures. ProtCID – ProtCID—a database of similar protein–protein interfaces in crystal structures of homologous proteins.
==== Resale exemptions and sales tax (United States) ==== Often, in the United States, wholesalers are not required to charge their buyers sales tax, if the buyer has a resale license in the state the wholesaler is located. Out-of-state buyers are not charged sale tax by wholesalers. Documentation requirements vary by state.
In Blood Diamond, DiCaprio starred as a diamond smuggler from Rhodesia who is involved in the Sierra Leone Civil War. While filming, he worked with 24 orphaned children from the SOS Children's Village in Maputo, Mozambique, and said he was touched by his interactions with them. To prepare, he spent six months in Africa, learned about camouflage from people in South African military and interviewed and recorded people in the country to improve his accent. The film received generally favorable reviews, and DiCaprio was noted for his South African accent, which is generally known as difficult to imitate. Claudia Puig of the USA Today approvingly highlighted DiCaprio's transition from a boy to a man on screen, and Ann Hornaday of The Washington Post similarly noted his growth as an actor since The Departed. DiCaprio received nominations for an Academy Award and a Golden Globe for Blood Diamond. In 2007, DiCaprio produced the comedy drama Gardener of Eden, which according to The Hollywood Reporter's Frank Scheck "lack[ed] the necessary dramatic urgency or black humor to connect with audiences". Later that year, he produced, co-wrote and narrated The 11th Hour, a documentary on the state of the natural environment that won the Earthwatch Environmental Film Award in 2008. DiCaprio's Appian Way produced Planet Green's Greensburg (2008–2010), which ran for three seasons. Set in Greensburg, Kansas, it is about rebuilding the town in a sustainable way after being hit by the 2007 Greensburg tornado.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.